Register entry
- Registered sites
- 0
- Active NDC listings
- 6
- Live patents
- 56
- Exclusivities
- 3
- Countries
- 0
Catalogue
Drug listings by form and route
66 active NDC listings: 6 human prescription drug. By marketing category: NDA 6.
| Dosage form | NDCs |
|---|---|
| for solution | 3 |
| capsule | 1 |
| solution | 1 |
| tablet, coated | 1 |
| Route | NDCs |
|---|---|
| oral | 6 |
| Labeller name on the listing | NDCs |
|---|---|
| acadia pharmaceuticals inc. | 6 |
Exclusivity
Patents and exclusivities
56| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7732615 | NUPLAZIDpimavanserin tartrate | substance, product | Jun 2028 |
| 7732615*PED | NUPLAZIDpimavanserin tartrate | use | Dec 2028 |
| 7601740 | NUPLAZIDpimavanserin tartrate | substance, product | Apr 2030 |
| 7601740*PED | NUPLAZIDpimavanserin tartrate | use | Oct 2030 |
| 9212204 | DAYBUE, DAYBUE STIXtrofinetide | use | Jan 2032 |
| 9212204*PED | DAYBUE, DAYBUE STIXtrofinetide | use | Jul 2032 |
| 10517860 | NUPLAZIDpimavanserin tartrate | use | Mar 2037 |
| 10953000 | NUPLAZIDpimavanserin tartrate | use | Mar 2037 |
| 10517860*PED | NUPLAZIDpimavanserin tartrate | use | Sept 2037 |
| 10953000*PED | NUPLAZIDpimavanserin tartrate | use | Sept 2037 |
| 10449185 | NUPLAZIDpimavanserin tartrate | product | Aug 2038 |
| 10646480 | NUPLAZIDpimavanserin tartrate | product | Aug 2038 |
| 10849891 | NUPLAZIDpimavanserin tartrate | product | Aug 2038 |
| 11452721 | NUPLAZIDpimavanserin tartrate | product | Aug 2038 |
| 10449185*PED | NUPLAZIDpimavanserin tartrate | use | Feb 2039 |
| 10646480*PED | NUPLAZIDpimavanserin tartrate | use | Feb 2039 |
| 10849891*PED | NUPLAZIDpimavanserin tartrate | use | Feb 2039 |
| 11452721*PED | NUPLAZIDpimavanserin tartrate | use | Feb 2039 |
| 11370755 | DAYBUE, DAYBUE STIXtrofinetide | substance, product | Aug 2040 |
| 11370755*PED | DAYBUE, DAYBUE STIXtrofinetide | use | Feb 2041 |
| 11827600 | DAYBUE, DAYBUE STIXtrofinetide | substance, product | Jul 2042 |
| 12492167 | DAYBUE, DAYBUE STIXtrofinetide | substance, product | Jul 2042 |
| 11827600*PED | DAYBUE, DAYBUE STIXtrofinetide | use | Jan 2043 |
| 12492167*PED | DAYBUE, DAYBUE STIXtrofinetide | use | Jan 2043 |
| Product | Exclusivity | Until |
|---|---|---|
| DAYBUETROFINETIDE | PED Paediatric | Sept 2030 |
| DAYBUE STIXTROFINETIDE | PED Paediatric | Sept 2030 |
| NUPLAZIDPIMAVANSERIN TARTRATE | PED Paediatric | Oct 2029 |
Catalogue
Marketed products
6| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Daybue | trofinetide | solution, oral | 63090-660NDA |
| Daybue Stix | trofinetide | for solution, oral | 63090-663NDA |
| Daybue Stix | trofinetide | for solution, oral | 63090-664NDA |
| Daybue Stix | trofinetide | for solution, oral | 63090-665NDA |
| NUPLAZID | pimavanserin tartrate | tablet, coated, oral | 63090-100NDA |
| NUPLAZID | pimavanserin tartrate | capsule, oral | 63090-340NDA |
Enquiry
Common questions
- Is Acadia Pharmaceuticals Inc. FDA approved?
- Acadia Pharmaceuticals Inc. holds no registered establishment of its own; 6 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Acadia Pharmaceuticals Inc. make?
- 6 products are listed under Acadia Pharmaceuticals Inc. in the openFDA NDC Directory, most often as for solution; capsule; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.